About the job
SpotLab is at the forefront of innovation in biopharmaceutical research, specializing in the development of advanced AI solutions for diagnostics. Supported by esteemed organizations such as the Gates Foundation and the European Commission, SpotLab was established in 2018 with the vision of creating trustworthy AI technologies that enhance healthcare accessibility, from blood cancers to neglected tropical diseases.
We are currently in search of a dynamic Business Development Lead to champion our AI oncology products, notably our groundbreaking MEDULAI platform designed for blood cancer diagnostics. In this role, you will be instrumental in crafting innovative business models that not only promise scalability but also substantial health benefits. You will be responsible for developing strategic market access frameworks and pioneering new markets for our state-of-the-art AI solutions.
This position reports directly to the CEO.
Key Responsibilities
Identify and cultivate new business opportunities within the medical technology sector, focusing on securing distribution agreements with med-tech companies that specialize in microscopy scanners and laboratory information systems (LIS).
Lead the negotiation and design of strategic agreements, including data licensing, intellectual property, IT deployments, and collaborative performance metrics.
Foster and maintain robust, trusting relationships with clients and strategic partners.
Contribute significantly to the formulation and execution of product commercialization strategies, encompassing market analysis, customer segmentation, and pricing strategies.
Advocate for our solutions within the digital pathology landscape.
Translate complex AI concepts into compelling narratives that resonate with diverse stakeholders, producing persuasive communication materials that enhance product promotion and drive commercial success.
Collaborate closely with internal teams across Technology, Clinical, and Operations to ensure product development aligns with market demands.
